Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine

• Status: Completed
• Trial end date: 2004-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Quinine remains the treatment of choice of hospitalised malaria cases. The long treatment duration of 7 days, and adverse reactions often hamper its adequate use. Reducing the treatment duration by adding sulfadoxine-pyrimethamine may enhance compliance and reduce side effects.

The efficacy of a 3-day treatment of quinine plus sulfadoxine-pyrimethamine for the treatment of hospitalised, uncomplicated malaria cases was assessed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Albert Schweitzer Hospital
• Treatments: Fanasil, pyrimethamine drug combination; Pyrimethamine; Quinine; Sulfadoxine

Criteria

Inclusion Criteria:

• Uncomplicated falciparum malaria

• Asexual parasitaemia between 20,000 and 200,000/µL

• No mixed plasmodial infection

• Fever with temperature above 38 °C or history of fever during the preceding 24 hours

• No effective anti-malarial treatment for the present attack

• Informed consent

Exclusion Criteria:

• Haemoglobin < 7 g/dL

• Packed-cell volume < 20%

• White cell count > 16,000/µL

• Platelet count < 40,000/µL

• Schizontaemia > 50/µL

• Impaired consciousness

• Convulsions or history of convulsions

• Concomitant diseases masking assessment of response